Ann: Appendix 4D - Half Year Report, page-3

Agree it looks OK and signs for second half are positive - esp. comments about reduced capital spend.

I'd give management the benefit of doubt on underlying figures; this year's abnormal relates to costs of the Nova acquisition (+ another acquisition not made) and last year they stripped out a gain on a disposal. No evidence (yet) of repeated 'abnormal' losses.